Compare Amgen, Inc. (AMGN) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs ProShares Ultra Gold ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while ProShares Ultra Gold ETF trades at $44.73. The key difference: Amgen, Inc. pays a 2.77% dividend while ProShares Ultra Gold ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | UGL | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $85.62 |
52-Week Low | $271.18 | $33.59 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
UGL, the ProShares Ultra Gold ETF, trades at $45.76, down 0.74% on the day, reflecting ongoing pressure in the gold market. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights gold's 25% decline from record highs amid Fed policy uncertainty and geopolitical tensions, though central bank buying provides some support. The ETF's leveraged structure amplifies daily gold price movements, impacting short-term performance.
The outlook for UGL hinges on gold price direction, with near-term risks from rising Treasury yields and inflation data. Opportunities exist if geopolitical tensions or dovish Fed shifts boost gold, but volatility remains high. Investors should note the ETF's decay risk from daily rebalancing in stagnant or volatile markets, making it more suitable for tactical plays than long-term holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
